Dr. Carol Moreno-Quinn Joins PhysioGenix’s Science Advisory Team

Milwaukee, WI (PRWEB) January 27, 2010 — Physiogenix, Inc., www.physiogenix.com, a world-leader in research services and solutions in the field of chronic disease, today announced that Dr. Carol Moreno-Quinn, M.D., Ph.D. will collaborate with the Company as a study director. Dr. Moreno-Quinn has extensive research experience in the fields of genetics, renal and cardiovascular diseases. Dr. Moreno-Quinn has spent five years as an Assistant Professor at the Medical College of Wisconsin. At the Medical College of Wisconsin, Dr. Moreno-Quinn is the Director of the Animal Core, which is responsible for a colony of 8,000 genetically diverse animals for the development of new models of disease and Co-Director of the Genomics Core, which manages the genotyping, sequencing and bioinformatics activities. She will work directly with clients to develop customized research programs in obesity and hypertension. “Dr.Moreno-Quinn brings extensive experience in research models and study design. She is a great addition to our team and will be key in achieving our goal of becoming a world-leader in chronic disease research services and solutions.” says Dr. Brian Curry, CEO of Physiogenix. Dr. Moreno-Quinn received her Ph.D. from Universidad de Murcia in Physiology and Pharmacology, where she focused on mechanistic research of the endocrine regulation of renal and cardiovascular functions. She also received her M.D. from the University of Murcia. About Physiogenix Healthcare trends. The United States has witnessed a dramatic change in the disease profile that contributes to morbidity and mortality. Today “chronic disease” defined by the CDC are non-communicable illnesses that are prolonged in duration, do not resolve spontaneously, and are rarely cured completely such as heart disease, cancer, and diabetes, which are the most prevalent and costly health issues. Every year chronic diseases cause 7 out of 10 deaths in the United States. This corresponds to 133 million Americans or nearly 1 in 2 adults living with a chronic disease. Chronic diseases also place a heavy burden on the United States healthcare system representing over 75% of all healthcare costs. A world-leader in chronic disease research services and solutions. Our goal is to be the world-leader in research services for organizations conducting studies involving therapeutics and medical devices for chronic diseases. Through our in-house capabilities and partnerships with outside experts, we seek to deliver the most comprehensive suite of solutions in our fields of expertise. Our services. We provide a full range of drug research services. From study design to reporting, our clients have come to appreciate our time sensitive, client focused services. Our capabilities include bioanalytical services, safety pharmacology, pharmacokinetics, drug metabolism, pharmacodynamics, phenotyping and specialized blood pressure monitoring. See Also: PRWeb

Read the full article at PhysioGenix Research Blog